Quick Answer
NovoCure Ltd reported Stockholders Equity of $340.47 million for fiscal year 2025.
NovoCure Ltd Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $340.47M | -5.5% |
| 2024 | $360.18M | -0.6% |
| 2023 | $362.50M | -17.8% |
| 2022 | $441.17M | +7.5% |
| 2021 | $410.49M | -13.9% |
| 2020 | $476.53M | +118.8% |
| 2019 | $217.79M | +94.0% |
| 2018 | $112.26M | -1.1% |
| 2017 | $113.56M | -20.2% |
| 2016 | $142.34M | -43.2% |
| 2015 | $250.82M | +156.3% |
| 2014 | $97.88M | -43.0% |
| 2013 | $171.78M | +247.6% |
| 2012 | $49.42M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $341.33M | -5.4% | -2.3% |
| June 30, 2025 | $349.44M | -3.4% | -3.5% |
| March 31, 2025 | $361.96M | +0.7% | +0.5% |
| December 31, 2024 | $360.18M | -0.6% | -0.2% |
| September 30, 2024 | $360.78M | -8.4% | -0.3% |
| June 30, 2024 | $361.75M | -13.0% | +0.7% |
| March 31, 2024 | $359.36M | -16.8% | -0.9% |
| December 31, 2023 | $362.50M | -17.8% | -7.9% |
- NovoCure Ltd showed a decrease of -5.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2012–2025 period, NovoCure Ltd’s stockholders equity has grown by 588.9% (from $49.42 million to $340.47 million).
- The most recent figure is from NovoCure Ltd’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: